JPRN-UMIN000027500已完成未知
Secondary analysis of "multicenter, prospective study on respiratory stability through recovery process from deterioration of heart failure in patients with chronic heart failure: PROST"(UMIN000019905). - Secondary analysis of PROST
Department of Cardiology, Fukuoka Saiseikai Futsukaichi Hospital0 个研究点目标入组 44 人开始时间: 2017年5月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Nothing particular
研究者
相似试验
进行中（未招募）
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcEUCTR2004-000882-36-FIGlaxoSmithKine Research & Development Limited424
进行中（未招募）
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemiaEUCTR2004-000882-36-SEGlaxoSmithKine Research & Development Limited424
进行中（未招募）
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemiaEUCTR2004-000882-36-DKGlaxoSmithKine Research & Development Limited424
进行中（未招募）
不适用
A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10 mg daily doses of GW501516 in subjects with low HDLcTreatment of dyslipidaemiaEUCTR2004-000882-36-LTGlaxoSmithKine Research & Development Limited424
进行中（未招募）
不适用
A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. - Le.P.Re studyEUCTR2009-011225-14-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA